Dextromethorphan Hydrobromide and Quinidine Sulphate

FDA Drug Profile — Dextromethorphan Hydrobromide and Quinidine Sulphate

Dextromethorphan Hydrobromide and Quinidine Sulphate is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Dextromethorphan Hydrobromide and Quinidine Sulphate. Available dosage form: capsule.

Drug details

Generic Name
Dextromethorphan Hydrobromide and Quinidine Sulphate
Brand Names
Dextromethorphan Hydrobromide and Quinidine Sulphate
Application Number
ANDA204196
Sponsor
Sun Pharmaceutical Industries, Inc.
NDC Codes
2
Dosage Forms
CAPSULE
Routes
ORAL
Active Ingredients
DEXTROMETHORPHAN HYDROBROMIDE, QUINIDINE SULFATE

Indications and Usage

1 INDICATIONS AND USAGE Dextromethorphan hydrobromide and quinidine sulfate capsules are indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Dextromethorphan hydrobromide and quinidine sulfate capsules is a combination product containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) indicated for the treatment of pseudobulbar affect (PBA). ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.